Mercer Global Advisors
CYTK icon

Mercer Global Advisors’s Cytokinetics CYTK Stock Holding History

Mercer Global Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$127K Buy
+1,485
New +$107K ﹤0.01% 3658

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Mercer Global Advisors's CYTK Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Cytokinetics (CYTK) in Q2 2026: 1,485 shares worth $127K. The stake represents ﹤0.01% of the portfolio and ranks #3658 among its holdings.

447 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Mercer Global Advisors held 1,485 shares of Cytokinetics worth $127K as of Q2 2026.
  • Cytokinetics was a new Mercer Global Advisors position in Q2 2026.
  • Cytokinetics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3658 holding.
  • 447 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.